White House regulatory reform agenda
This article was originally published in The Gray Sheet
Executive Summary
Office of Management and Budget is taking nominations for regs and guidance documents that impose "especially large burdens on small businesses and other small entities without an adequate benefit justification" for review. Issued March 18, 1OMB's draft report to Congress on the costs and benefits of federal regulations carries a 60-day comment period. HHS Secretary Thompson recently established a department-wide advisory panel on regulatory reform, set to meet March 20-21 in Phoenix. That panel is independently seeking comments on burdensome regulations (2"The Gray Sheet" March 18, 2002, p. 14). OMB also states that a "scientific advisory panel" including health and medical science experts will meet twice a year to evaluate Office of Information and Regulatory Affairs activities...
You may also be interested in...
Blood Safety Authority Shift To CDRH Opposed By Blood Centers
Legislation shifting responsibility for the regulation of blood safety screening tests from FDA's Center for Biologics Evaluation and Research to the device center puts an enormous burden on blood organizations, according to America's Blood Centers (ABC)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.